1. Zalcman, G, Mazieres, J, Margery, J, et al Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 1405–1414.
Google Scholar | Crossref | Medline | ISI2. Thapa, B, Salcedo, A, Lin, X, et al The immune microenvironment, genome-wide copy number aberrations, and survival in mesothelioma. J Thorac Oncol 2017; 12: 850–859.
Google Scholar | Crossref | Medline3. Yamada, N, Oizumi, S, Kikuchi, E, et al CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol Immunother 2010; 59: 1543–1549.
Google Scholar | Crossref | Medline4. Sharpe, A, Pauken, K. The diverse functions of the PD1inhibitory pathway. Nat Rev Immunol 2018; 18: 153–167.
Google Scholar | Crossref | Medline5. Bueno, R, Stawiski, E, Goldstein, L, et al Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016; 48: 407–416.
Google Scholar | Crossref | Medline6. Cheng, JQ, Jhanwar, SC, Klein, WM, et al p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 5547–5551.
Google Scholar | Medline | ISI7. Hirao, T, Bueno, R, Chen, CJ, et al Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002; 23: 1127–1130.
Google Scholar | Crossref | Medline | ISI8. Toyooka, S, Carbone, M, Toyooka, KO, et al Progressive aberrant methylation of the RASSF1A gene in simian virus 40 infected human mesothelial cells. Oncogene 2002; 21: 4340–4344.
Google Scholar | Crossref | Medline9. Fischer, JR, Ohnmacht, U, Rieger, N, et al Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma. Lung Cancer 2006; 54: 109–116.
Google Scholar | Crossref | Medline10. Maille, E, Brosseau, S, Hanoux, V, et al MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial. Br J Cancer 2019; 120: 387–397.
Google Scholar | Crossref | Medline11. Tranchant, R, Quetel, L, Tallet, A, et al Co-occurring mutations of tumor suppressor genes, LATS2 and NF2, in malignant pleural mesothelioma. Clin Cancer Res 2017; 23: 3191–3202.
Google Scholar | Crossref | Medline12. Wang, G, Lu, X, Dey, P, et al Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discov 2016; 6: 80–95.
Google Scholar | Crossref | Medline | ISI13. Rehrauer, H, Wu, L, Blum, W, et al How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations. Oncogene 2018; 37: 2645–2659.
Google Scholar | Crossref | Medline14. Hirsch, F, McElhinny, A, Stanforth, D, et al PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol 2017; 12: 208–222.
Google Scholar | Crossref | Medline | ISI15. Tsao, M, Kerr, K, Kockx, M, et al PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project. J Thorac Oncol 2018; 13: 1302–1311.
Google Scholar | Crossref | Medline16. Adam, J, Le Stang, N, Rouquette, I, et al Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol 2018; 29: 953–958.
Google Scholar | Crossref | Medline17. Mansfield, AS, Roden, AC, Peikert, T, et al B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis. J Thorac Oncol 2014; 9: 1036–1040.
Google Scholar | Crossref | Medline | ISI18. Cedres, S, Ponce-Aix, S, Zugazagoitia, J, et al Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM). PLoS ONE 2015; 10: e0121071.
Google Scholar | Crossref | Medline19. Brosseau, S, Danel, C, Scherpereel, A, et al Shorter survival in malignant pleural mesothelioma patients with high PD-L1 expression associated with sarcomatoid or biphasic histology subtype: a series of 214 cases from the bio-MAPS cohort. Clin Lung Cancer 2019; 20: e564–e575.
Google Scholar | Crossref | Medline20. Khanna, S, Thomas, A, Abate-Daga, D, et al Malignant mesothelioma effusions are infiltrated by CD3þ T cells highly expressing PD-L1 and the PD-L1þ tumor cells within these effusions are susceptible to ADCC by the anti–PD-L1 antibody avelumab. J Thorac Oncol 2016; 11: 1993–2005.
Google Scholar | Crossref | Medline21. Inaguma, S, Lasota, J, Wang, Z, et al Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma. Hum Pathol 2018; 71: 1–7.
Google Scholar | Crossref | Medline22. Ma, L, Wang, J, Lin, J, et al Cluster of differentiation 166 (CD166) regulated by phosphatidylinositide 3-kinase (PI3K)/AKT signaling to exert its anti-apoptotic role via yes-associated protein (YAP) in liver cancer. J Biol Chem 2014; 289: 6921–6933.
Google Scholar | Crossref | Medline | ISI23. de Reynies, A, Jaurand, MC, Renier, A, et al Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 2014; 20: 1323–1334.
Google Scholar | Crossref | Medline24. Calabro, L, Morra, A, Fonsatti, E, et al Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14: 1104–1111.
Google Scholar | Crossref | Medline | ISI25. Calabro, L, Morra, A, Fonsatti, E, et al Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med 2015; 3: 301–309.
Google Scholar | Crossref | Medline26. Maio, M, Scherpereel, A, Calabro, L, et al Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol 2017; 18: 1261–1273.
Google Scholar | Crossref | Medline27. Alley, EW, Lopez, J, Santoro, A, et al Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol 2017; 18: 623–630.
Google Scholar | Crossref | Medline28. Kindler, H, Karrison, T, Tan, Y-HC, et al Phase II trial of pembrolizumab in patients with malignant mesothelioma (MM): interim analysis. J Thorac Oncol 2017; 12: S293–S294; OA13.03.
Google Scholar | Crossref | Medline29. Mauti, L, Klingbiel, D, Schmid, S, et al Pembrolizumab as second or further line treatment in relapsed malignant pleural mesothelioma: a Swiss registry study. Ann Oncol 2017; 28: abstr. 1615O.
Google Scholar | Crossref30. Quispel-Janssen, J, van der Noort, V, de Vries, J, et al Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 2018; 13: 1569–1576.
Google Scholar | Crossref | Medline31. Okada, M, Kijima, T, Aoe, K, et al Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT). Clin Cancer Res 2019; 25: 5485–5492.
Google Scholar | Crossref | Medline32. Hassan, R, Thomas, A, Nemunaitis, J, et al Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN solid tumor. J Clin Oncol 2018; 36(Suppl.): abstr 8563.
Google Scholar | Crossref33. Popat, S, Curioni-Fontecedro, A, Dafni, U, et al A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol 2020; 31: 1734–1745.
Google Scholar | Crossref | Medline34. Fenell, D, Ottensmeier, C, Califano, R, et al Nivolumab versus placebo in relapsed malignant mesothelioma: the CONFIRM phase 3 trial. J Thorac Oncol 2021; 16(Suppl.): Abstr PS01.11.
Google Scholar35. Yap, T, Nakagawa, K, Fujimoto, N, et al Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 2021; 9: 613–621.
Google Scholar | Crossref | Medline36. Scherpereel, A, Mazieres, J, Greillier, L, et al Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol 2019; 20: 239–253.
Google Scholar | Crossref | Medline37. Disselhorst, M, Quispel-Janssen, J, Lalezari, F, et al Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med 2019; 7: 260–270.
Google Scholar | Crossref | Medline38. Calabro, L, Morra, A, Giannarelli, D, et al Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med 2018; 6: 451–460.
Google Scholar | Crossref | Medline39. Baas, P, Scherpereel, A, Nowak, A, et al First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet 2021; 397: 375–386.
Google Scholar | Crossref | Medline40. Zalcman, G, Mazieres, J, Greillier, L, et al Second or 3rd line nivolumab (Nivo) versus Nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: up-dated results of the IFCT-1501 MAPS2 randomized phase 2 trial. Ann Oncol 2017; 28: Abstract LBA58_PR.
Google Scholar | Crossref | Medline41. Ferrara, R, Mezquita, L, Texier, M, et al Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol 2018; 4: 1543–1552.
Google Scholar | Crossref | Medline42. Champiat, S, Ferrara, R, Massard, C, et al Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol 2018; 15: 748–762.
Google Scholar | Crossref | Medline43. Kas, B, Talbot, H, Ferrara, R, et al Clarification of definitions of hyperprogressive disease during immunotherapy for non-small cell lung cancer. JAMA Oncol 2020; 6: 1039–1046.
Google Scholar | Crossref | Medline44. Nowak, A, Lesterhuis, W, Kok, P, et al Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol 2020; 21: 1213–1223.
Google Scholar | Crossref | Medline